DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Rockwell Medical, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rockwell Medical, Inc. (Rockwell Medical or the Company) (NASDAQ: RMTI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Rockwell Medical had knowledge that the Centers for Medicare and Medicaid Services would not pursue the Companys plan for reimbursement for Triferic. The Companys estimated reserves on form 10-Q for the quarter ending March 31, 2018, were misstated. Rockwell Medical suffered from material weakness in controls for financial reporting. Robert L. Chioini, Rockwells former Chief Executive Officer, failed to inform the Companys auditors, corporate counsel, and independent board members with important information about Triferic. Based on these facts, the Companys public statements about business operations, prospects, and results were false and materially misleading.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at, or by email at [email protected].

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.